Hickey Benjamin
Insider CIK 1753055 · HALO SVP, Chief Commerical Officer · BMY President, RayzeBio Org. · MRTX EVP, Chief Commercial Officer · SURF Director · MURA Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| BMY BRISTOL MYERS SQUIBB CO | A Award deriv | 2026-03-10 | 2026-03-12 | 17,143 | — | $0 | 17,143 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | A Award deriv | 2026-03-10 | 2026-03-12 | 11,429 | — | $0 | 11,429 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | M Exercise deriv | 2026-02-27 | 2026-03-03 | 3,286 | — | $0 | 3,286 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | F Tax w/h | 2026-02-27 | 2026-03-03 | 1,672 | $62.37 | $104.3K | 16,672 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | M Exercise | 2026-02-27 | 2026-03-03 | 3,286 | — | $0 | 18,344 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | M Exercise deriv | 2026-02-01 | 2026-02-03 | 10,079 | — | $0 | 10,079 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | F Tax w/h | 2026-02-01 | 2026-02-03 | 3,810 | $55.05 | $209.7K | 15,058 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | M Exercise | 2026-02-01 | 2026-02-03 | 10,079 | — | $0 | 18,868 | SEC↗ |
| MURA Mural Oncology plc | D To issuer deriv | 2025-12-05 | 2025-12-05 | 8,462 | — | $0 | 0 | SEC↗ |
| MURA Mural Oncology plc | D To issuer deriv | 2025-12-05 | 2025-12-05 | 8,637 | — | $0 | 0 | SEC↗ |
| MURA Mural Oncology plc | D To issuer deriv | 2025-12-05 | 2025-12-05 | 15,021 | — | $0 | 0 | SEC↗ |
| MURA Mural Oncology plc | A Award deriv | 2025-06-11 | 2025-06-13 | 8,637 | — | $0 | 8,637 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | S Sale | 2025-05-09 | 2025-05-13 | 97 | $38.01 | $3.7K | 0 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | A Award deriv | 2025-03-10 | 2025-03-12 | 13,389 | — | $0 | 13,389 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | A Award deriv | 2025-03-10 | 2025-03-12 | 20,084 | — | $0 | 20,084 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | M Exercise deriv | 2025-03-01 | 2025-03-04 | 3,286 | — | $0 | 6,572 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | M Exercise | 2025-03-01 | 2025-03-04 | 3,286 | — | $0 | 10,419 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | F Tax w/h | 2025-03-01 | 2025-03-04 | 1,630 | $59.62 | $97.2K | 8,789 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | M Exercise deriv | 2025-02-01 | 2025-02-04 | 10,078 | — | $0 | 20,158 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | F Tax w/h | 2025-02-01 | 2025-02-04 | 3,725 | $58.95 | $219.6K | 7,133 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | M Exercise | 2025-02-01 | 2025-02-04 | 10,078 | — | $0 | 10,858 | SEC↗ |
| MURA Mural Oncology plc | A Award deriv | 2024-05-30 | 2024-06-03 | 8,462 | $3.35 | $28.3K | 8,462 | SEC↗ |
| MURA Mural Oncology plc | A Award deriv | 2024-05-30 | 2024-06-05 | 8,462 | — | $0 | 8,462 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | A Award deriv | 2024-03-10 | 2024-03-12 | 5,805 | — | $0 | 5,805 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | A Award deriv | 2024-03-10 | 2024-03-12 | 3,870 | — | $0 | 3,870 | SEC↗ |
| BMY BRISTOL MYERS SQUIBB CO | A Award deriv | 2024-03-01 | 2024-03-04 | 9,858 | — | $0 | 9,858 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | D To issuer deriv | 2024-01-23 | 2024-01-23 | 43,328 | — | $0 | 0 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | D To issuer deriv | 2024-01-23 | 2024-01-23 | 2,128 | — | $0 | 0 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | D To issuer | 2024-01-23 | 2024-01-23 | 17,021 | — | $0 | 0 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | D To issuer | 2024-01-23 | 2024-01-23 | 72,206 | — | $0 | 17,021 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | D To issuer | 2024-01-23 | 2024-01-23 | 27,801 | — | $0 | 89,227 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2024-01-16 | 2024-01-18 | 631 | $59.02 | $37.2K | 117,028 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2024-01-16 | 2024-01-18 | 966 | $59.02 | $57.0K | 117,659 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2024-01-08 | 2024-01-09 | 2,090 | $58.92 | $123.1K | 118,625 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | A Award | 2023-12-29 | 2024-01-03 | 17,021 | $58.75 | $1000.0K | 120,715 | SEC↗ |
| MURA Mural Oncology plc | A Award deriv | 2023-12-14 | 2023-12-18 | 15,021 | — | $0 | 15,021 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2023-12-13 | 2023-12-14 | 2,220 | $56.67 | $125.8K | 103,694 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | A Award | 2023-08-09 | 2023-08-10 | 22,297 | $37.00 | $825.0K | 105,914 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | A Award deriv | 2023-01-20 | 2023-01-24 | 45,456 | — | $0 | 45,456 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | A Award | 2023-01-20 | 2023-01-24 | 36,394 | — | $0 | 83,617 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2023-01-17 | 2023-01-19 | 619 | $42.38 | $26.2K | 47,223 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2023-01-17 | 2023-01-19 | 947 | $42.38 | $40.1K | 47,842 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2023-01-09 | 2023-01-10 | 2,088 | $45.37 | $94.7K | 48,789 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2022-12-21 | 2022-12-21 | 3,248 | $40.41 | $131.3K | 50,877 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | A Award | 2022-12-19 | 2022-12-21 | 19,149 | — | $0 | 54,125 | SEC↗ |
| SURF Surface Oncology, Inc. | A Award deriv | 2022-06-08 | 2022-06-10 | 24,000 | — | $0 | 24,000 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2022-01-18 | 2022-01-18 | 627 | $120.48 | $75.5K | 34,976 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | A Award deriv | 2022-01-14 | 2022-01-18 | 17,821 | — | $0 | 17,821 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | A Award | 2022-01-14 | 2022-01-18 | 10,755 | — | $0 | 35,603 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2022-01-07 | 2022-01-07 | 1,964 | $135.94 | $267.0K | 24,848 | SEC↗ |
| SURF Surface Oncology, Inc. | A Award deriv | 2022-01-03 | 2022-01-05 | 24,000 | — | $0 | 24,000 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | M Exercise deriv | 2021-03-19 | 2021-03-22 | 2,369 | — | $0 | 30,116 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2021-03-19 | 2021-03-22 | 588 | $175.54 | $103.2K | 28,593 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2021-03-19 | 2021-03-22 | 1,350 | $176.42 | $238.2K | 27,243 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2021-03-19 | 2021-03-22 | 431 | $177.71 | $76.6K | 26,812 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | M Exercise | 2021-03-19 | 2021-03-22 | 2,369 | $114.33 | $270.8K | 29,181 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | A Award deriv | 2021-01-15 | 2021-01-20 | 10,979 | — | $0 | 10,979 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | A Award | 2021-01-15 | 2021-01-20 | 7,023 | — | $0 | 26,812 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2021-01-07 | 2021-01-08 | 9 | $215.31 | $1.9K | 21,858 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | S Sale | 2021-01-07 | 2021-01-08 | 2,069 | $216.33 | $447.6K | 19,789 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | A Award deriv | 2020-01-06 | 2020-01-08 | 32,485 | — | $0 | 32,485 | SEC↗ |
| MRTX Mirati Therapeutics, Inc. | A Award | 2020-01-06 | 2020-01-08 | 21,867 | — | $0 | 21,867 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | M Exercise deriv | 2019-10-01 | 2019-10-01 | 20,216 | — | $0 | 60,647 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | M Exercise | 2019-10-01 | 2019-10-01 | 20,216 | — | $0 | 20,216 | SEC↗ |
| HALO HALOZYME THERAPEUTICS, INC | F Tax w/h | 2019-10-01 | 2019-10-01 | 6,990 | $15.46 | $108.1K | 13,226 | SEC↗ |
| HALO HALOZYME THERAPEUTICS INC | A Award deriv | 2019-02-12 | 2019-02-14 | 71,602 | — | $0 | 71,602 | SEC↗ |
| HALO HALOZYME THERAPEUTICS INC | A Award deriv | 2019-02-12 | 2019-02-14 | 37,538 | — | $0 | 37,538 | SEC↗ |
| HALO HALOZYME THERAPEUTICS INC | A Award deriv | 2018-10-01 | 2018-10-03 | 80,863 | — | $0 | 80,863 | SEC↗ |
| HALO HALOZYME THERAPEUTICS INC | A Award deriv | 2018-10-01 | 2018-10-03 | 149,516 | — | $0 | 149,516 | SEC↗ |